MCID: RHN004
MIFTS: 57

Rhinitis

Categories: Bone diseases, Respiratory diseases, Smell/Taste diseases

Aliases & Classifications for Rhinitis

MalaCards integrated aliases for Rhinitis:

Name: Rhinitis 12 29 54 44 15 17 70
Runny Nose 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4483
MeSH 44 D012220
NCIt 50 C34986
SNOMED-CT 67 70076002
UMLS 70 C0035455

Summaries for Rhinitis

Disease Ontology : 12 A upper respiratory infectious disease which involves irritation and inflammation of the mucous membrane of the nose due to viruses, bacteria or irritants. The inflammation results in generation of excessive amounts of mucus leading to runny nose, as well as nasal congestion and post-nasal drip.

MalaCards based summary : Rhinitis, also known as runny nose, is related to chronic rhinitis and vasomotor rhinitis, and has symptoms including rhinorrhea, sneezing and sinus congestion. An important gene associated with Rhinitis is IL13 (Interleukin 13), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Dexlansoprazole and Lansoprazole have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and eye, and related phenotypes are hematopoietic system and immune system

Wikipedia : 73 Rhinitis, also known as coryza, is irritation and inflammation of the mucous membrane inside the nose.... more...

Related Diseases for Rhinitis

Diseases in the Rhinitis family:

Chronic Rhinitis

Diseases related to Rhinitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 651)
# Related Disease Score Top Affiliating Genes
1 chronic rhinitis 32.9 RNASE3 IL5 IL4 IL13 HRH1 EPX
2 vasomotor rhinitis 32.9 RNASE3 KNG1 IL5 IL13
3 ige responsiveness, atopic 32.6 RNASE3 IL5 IL4R IL4 IL13 IGHE
4 respiratory syncytial virus infectious disease 32.3 IL5 IL13 CCL5
5 pollen allergy 32.3 RNASE3 IL5 IL4R IL13 IGHE ICAM1
6 allergic rhinitis 32.1 VCAM1 RNASE3 NR3C1 NGF KNG1 IL5
7 giant papillary conjunctivitis 31.9 RNASE3 IL4 CXCL8 CCL11
8 churg-strauss syndrome 31.9 RNASE3 IL5 CYSLTR1 CXCL8 CCL11
9 allergic conjunctivitis 31.8 RNASE3 IL5 IL4 IL13 IGHE ICAM1
10 common cold 31.7 RNASE3 IL5 IL4 IL13 ICAM1 CYSLTR1
11 allergic asthma 31.6 VCAM1 RNASE3 IL5 IL4R IL4 IL13
12 cytokine deficiency 31.6 IL5 IL13
13 hypereosinophilic syndrome 31.5 RNASE3 IL5 IL4 IL13 IGHE EPX
14 conjunctivitis 31.5 RNASE3 IL5 IL4 IL13 IGHE ICAM1
15 respiratory allergy 31.5 RNASE3 IL5 IL4R IL4 IL13 IGHE
16 dermatitis 31.4 RNASE3 IL5 IL4R IL4 IL13 IGHE
17 urticaria 31.4 RNASE3 IL5 IL4 IL13 IGHE HRH1
18 otitis media 31.4 RNASE3 IL5 IL4 IGHE ICAM1 CXCL8
19 allergic disease 31.3 RNASE3 NR3C1 IL5 IL4R IL4 IL13
20 dermatitis, atopic 31.2 VCAM1 RNASE3 NGF IL5 IL4R IL4
21 sleep apnea 31.2 VCAM1 ICAM1 CXCL8
22 food allergy 31.2 RNASE3 IL5 IL4R IL4 IL13 IGHE
23 gastroesophageal reflux 31.1 IL5 IL4 CXCL8 CCL11
24 exercise-induced bronchoconstriction 31.1 RNASE3 IL13 CYSLTR1
25 bronchitis 31.0 RNASE3 IL5 IL4 IL13 CXCL8 CCL5
26 acute asthma 31.0 RNASE3 IL5 IL4
27 chronic urticaria 31.0 RNASE3 IL4 IL13 IGHE HRH1 CYSLTR1
28 aspergillosis 30.8 IL5 IL4 EPX CXCL8 CCL5
29 chronic asthma 30.8 RNASE3 IL5 IL4 IL13 IGHE CCL11
30 leprosy 3 30.8 IL5 IL4 IL13 CXCL8
31 intrinsic asthma 30.8 RNASE3 IL5 IL4 IL13 IGHE
32 proteasome-associated autoinflammatory syndrome 1 30.8 VCAM1 RNASE3 IL5 IL4 IL13 IGHE
33 drug allergy 30.7 IL5 IL4R IL13 IGHE CYP3A4
34 fibromyalgia 30.7 POMC NGF CXCL8
35 pneumonia 30.6 IL5 IL4 IL13 CXCL8 CCL5 CCL11
36 chlamydia 30.6 IL5 IL4 CXCL8
37 angioedema 30.6 KNG1 IL5 IGHE HRH1
38 pulmonary disease, chronic obstructive 30.6 RNASE3 NR3C1 IL5 IL4 IL13 CXCL8
39 irritable bowel syndrome 30.6 POMC NGF IL4 CXCL8
40 middle ear disease 30.6 IL5 IL4 CXCL8
41 contact dermatitis 30.6 VCAM1 NGF IL5 IL4 ICAM1 CXCL8
42 graves' disease 30.5 IL4 IL13 ICAM1 CCL5
43 lung disease 30.5 RNASE3 IL5 IL4 IL13 ICAM1 CXCL8
44 milk allergy 30.5 RNASE3 IL5 IL4 IL13 IGHE
45 cough variant asthma 30.5 RNASE3 NGF IL5 IL4 IGHE
46 egg allergy 30.5 IL5 IL4 IL13 IGHE
47 cystic fibrosis 30.5 RNASE3 IL5 IL4 IL13 ICAM1 CXCL8
48 anxiety 30.5 POMC NR3C1 NGF CYP3A4
49 allergic bronchopulmonary aspergillosis 30.5 IL5 IL4 IGHE EPX
50 latex allergy 30.4 RNASE3 IL5 IL4 IL13 IGHE

Graphical network of the top 20 diseases related to Rhinitis:



Diseases related to Rhinitis

Symptoms & Phenotypes for Rhinitis

UMLS symptoms related to Rhinitis:


rhinorrhea; sneezing; sinus congestion; nasal congestion (finding); nasal irritation; posterior rhinorrhea

MGI Mouse Phenotypes related to Rhinitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.93 CCL11 CCL5 EPX HRH1 ICAM1 IL13
2 immune system MP:0005387 9.77 CCL11 CCL5 CYSLTR1 EPX HRH1 ICAM1
3 respiratory system MP:0005388 9.23 CCL11 CYSLTR1 FOXJ1 IL13 IL4 IL4R

Drugs & Therapeutics for Rhinitis

Drugs for Rhinitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 282)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
2
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
3
mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7
4
Loratadine Approved, Investigational Phase 4 79794-75-5 3957
5
Budesonide Approved Phase 4 51333-22-3 63006 5281004
6
Cetirizine Approved Phase 4 83881-51-0 2678
7
Desloratadine Approved, Investigational Phase 4 100643-71-8 124087
8
Omalizumab Approved, Investigational Phase 4 242138-07-4
9
Fexofenadine Approved, Investigational Phase 4 83799-24-0 3348
10
Terfenadine Approved, Withdrawn Phase 4 50679-08-8 5405
11
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
12
Xylometazoline Approved, Investigational Phase 4 526-36-3 5709
13
Ethanol Approved Phase 4 64-17-5 702
14
Capsaicin Approved Phase 4 404-86-4 1548943
15
Theophylline Approved Phase 4 58-55-9 2153
16
Adenosine Approved, Investigational Phase 4 58-61-7 60961
17
Prazosin Approved Phase 4 19216-56-9 4893
18
Doxazosin Approved Phase 4 74191-85-8 3157
19
Promethazine Approved, Investigational Phase 4 60-87-7 4927
20
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
21
Sodium citrate Approved, Investigational Phase 4 68-04-2
22
Montelukast Approved Phase 4 158966-92-8 5281040
23
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
24
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
25
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
26
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
27
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
28
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
29
Resveratrol Investigational Phase 4 501-36-0 445154
30
Tranilast Investigational Phase 4 53902-12-8 93543
31
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
32 Purple Butterbur Phase 4
33 Proton Pump Inhibitors Phase 4
34 Pharmaceutical Solutions Phase 4
35 Albuterol Phase 4
36 Ophthalmic Solutions Phase 4
37 Tocolytic Agents Phase 4
38 Calcium, Dietary Phase 4
39 Anti-Infective Agents, Local Phase 4
40 Central Nervous System Stimulants Phase 4
41 Anesthetics Phase 4
42 Cholinergic Antagonists Phase 4
43
Salmeterol xinafoate Phase 4 94749-08-3 56801
44
Ethylene Phase 4 74-85-1 6325
45
Beclomethasone Phase 4 4419-39-0 20469
46 Acidophilus Phase 4
47 Gastrointestinal Agents Phase 4
48 Antiemetics Phase 4
49 Fluticasone-Salmeterol Drug Combination Phase 4
50 Lubricant Eye Drops Phase 4

Interventional clinical trials:

(show top 50) (show all 1040)
# Name Status NCT ID Phase Drugs
1 A Randomized, Parallel, Double-blind, Multi-center, Comparative Study to Exploratively Evaluate the Efficacy and Safety of Cosalin® Monotherapy vs. Cosalin® and Xarlin® Combination Therapy in Patients With Allergic Rhinitis Unknown status NCT01062139 Phase 4 Xarlin (Levocetirizine);Cosalin (Petasites hybridus CO2 extract)
2 Comparison of the Effect of Montelukast and Cetirizine on Allergic Inflammation Measured by Exhaled Nitric Oxide Concentration in Children With Seasonal Allergic Rhinitis Unknown status NCT00488176 Phase 4 montelukast;cetirizine;montelukast and cetirizine;placebo
3 Evaluating Factors Involved in Dymista's Superior Clinical Efficacy to Fluticasone Propionate in the Treatment of Seasonal Allergic Rhinitis Unknown status NCT02402465 Phase 4 Placebo;Fluticasone propionate;Fluticasone/Azelastine nasal spray
4 Real Life Proof-of-Concept Study to Assess the Effect of Methylcellulose as add-on "Seal" to the In-season Pharmacologic Rescue Treatment in Subjects With Allergic Rhinitis Unknown status NCT02557269 Phase 4 Xylometazoline - intranasal application;Azelastine - intranasal application;Mometasone furoate - intranasal application;Hydroxyl-propyl-methyl cellulose powder - intranasal application;Bilastine 20 mg;Prednisolone 5 mg
5 Assessment of Effectiveness and Safety of Annual Sublingual Immunotherapy in Children With Bronchial Asthma and/or Allergic Rhinitis Allergic to House Dust Mites Unknown status NCT01052610 Phase 4 sublingual house dust mites allergen extract;placebo in sublingual applicator
6 AZE/FLU Nasal Spray on Symptom Control, Nasal Mediators and Nasal Hyperresponsiveness in Allergic Rhinitis (AR) Unknown status NCT02238353 Phase 4 azelastine + fluticasone;Placebo
7 The Effect of Cetirizine on Bronchoconstriction in Patients With Allergic Rhinitis and Wheezing in the Pediatric Emergency Department Unknown status NCT03340740 Phase 4 Cetirizine Hydrochloride 1 MG/ML;Placebo - Concentrate
8 SINOL + MucoAd™ (SMAN) Evaluation Trial: A Double-Blind, Cross-Over Comparison of SINOL and SMAN in Subjects With Congestion Due to Allergic Rhinitis Unknown status NCT00825656 Phase 4 Sinol or Sinol-M nasal spray
9 The Relationship Between Gastroesophageal Reflux and Pediatric Rhinitis: Significance of Pale/Blue Colored Turbinate. A Randomized Controlled Trial Unknown status NCT02278081 Phase 4 lansoprazole;placebo
10 The Evaluation of Singulair for the Treatment of Non-Allergic Rhinitis Eosinophil Syndrome (NARES) Unknown status NCT00406094 Phase 4 montelukast;placebo
11 Changes in Exhaled Breath Temperature During the Pollen Season in Subjects With Allergic Rhinoconjunctivitis Sensitized to Grasses and Effect of Sublingual Immunotherapy Unknown status NCT01785394 Phase 4 5 grass allergen extract
12 A Trial of Immunological Outcomes of Sublingual Immunotherapy for House Dust Mite (D. Pteronyssinus) Allergy Completed NCT00250263 Phase 4 (agent for immunotherapy) Staloral;Placebo
13 Phase 4- The Role of Montelukast on Perennial Rhinitis and Associated Sleep Disturbance and Daytime Somnolence Completed NCT00590772 Phase 4 montelukast;placebo
14 The Impact of Grass SLIT Treatment on Birch Pollen Induced Allergic Rhinitis - a Pilot Evaluation Completed NCT02394600 Phase 4 Grastek®;Placebo
15 Quantitative-Qualitative Clinical Trial to Evaluate the Effectiveness of Individualized Homeopathic Treatment in Perennial Allergic Rhinitis Completed NCT00822406 Phase 4 homeopathic medicine;placebo
16 Evaluation of the Sensory Attributes of Olopatadine 0.6% and Azelastine 137mcg Nasal Sprays in Patients w/Allergic Rhinitis Completed NCT00772304 Phase 4 Olopatadine 0.6% / Azelastine 137 mcg
17 The Impact Of The Addition Of Budesonide To Low-Pressure, High-Volume Saline Sinus Irrigation For Chronic Rhinosinusitis Completed NCT02696850 Phase 4 Budesonide;Saline alone
18 Comparison of Effectiveness and Safety of Sublingual Immunotherapy in Children With Allergic Rhinitis Allergic to Grass Pollen Completed NCT00698594 Phase 4
19 Preference Evaluation of Clarinex Tablets vs. Zyrtec Tablets in Subjects With Symptomatic Allergic Rhinitis Completed NCT00794846 Phase 4 Desloratadine 5 mg (Clarinex);Cetirizine (Zyrtec)
20 Preference Evaluation of Clarinex Tablets vs. Zyrtec Tablets in Subjects With Symptomatic Allergic Rhinitis Completed NCT00794495 Phase 4 Desloratadine 5 mg (Clarinex);Cetirizine (Zyrtec)
21 Preference Evaluation of Clarinex Tablets vs. Zyrtec Tablets in Subjects With Symptomatic Allergic Rhinitis Completed NCT00794599 Phase 4 Desloratadine 5 mg (Clarinex);Cetirizine (Zyrtec)
22 Study 200165, A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Compare the Efficacy of a 2-Week Treatment With Fluticasone Propionate Nasal Spray Versus Cetirizine in Adult Subjects With Seasonal Allergic Rhinitis (SAR) Completed NCT01916226 Phase 4 FPNS;FPNS Placebo;Cetirizine;Cetirizine Placebo
23 A Double-Blind Placebo-Controlled, Randomized, Parallel-Group, Single-Site Study of Mometasone Furoate Nasal Spray (MFNS) In Subjects With Sleep-disordered Breathing Associated With Perennial Allergic Rhinitis (PAR) Using Home-Monitored Cardio-Respiratory Methodology. Completed NCT00359216 Phase 4 Mometasone furoate nasal spray;Placebo
24 A Double-Blind, Parallel, Randomized, Placebo Controlled Trial to Evaluate Onset of Action of Loratadine and Fexofenadine in Subjects With Seasonal Allergic Rhinitis in a Pollen Challenge Chamber Completed NCT01469234 Phase 4 loratadine;fexofenadine;placebo to loratadine;placebo to fexofenadine
25 Allergic Rhinitis Changes the Sinus Microbiome Completed NCT01852513 Phase 4 QNASL;Placebo nasal spray
26 A Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study Using Subjective and Objective Measures to Evaluate the Clinical Efficacy of Mometasone Furoate Nasal Spray (MFNS) Following Initial and Maintenance Dosing in Subjects With Allergen-Induced Seasonal Allergic Rhinitis (SAR) in an Environmental Exposure Chamber (EEC) Completed NCT00491504 Phase 4 Mometasone Furoate Nasal Spray
27 Efficacy and Safety of Loratadine-Betamethasone Oral Solution (1 mg/0.05 mg/1 mL) for Initial Treatment of Severe Perennial Allergic Rhinitis in School Age Children Completed NCT00963573 Phase 4 Loratadine;Betamethasone
28 A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel Group Study of the 12 Month Effect of Treatment With Once Daily Triamcinolone Acetonide (NASACORT® AQ Nasal Spray 110 μg) on the Growth Velocity of Children, 3 to 9 Years of Age, With Perennial Allergic Rhinitis (PAR) Completed NCT00449072 Phase 4 TAA-AQ, Nasacort® AQ;Claritin®
29 Efficacy of Levocetirizine in the Treatment of Nasal Obstruction Due to Perennial Rhinitis Completed NCT00439712 Phase 4 Levocetirizine;Placebo
30 A Comparison of Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis Completed NCT00435461 Phase 4 Fluticasone furoate and fexofenadine
31 A Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Multicenter Study of Mometasone Furoate Nasal Spray on Sleep Disturbances and Daytime Somnolence in Subjects With Symptomatic Seasonal Allergic Rhinitis Completed NCT00358527 Phase 4 Mometasone Furoate Nasal Spray (MFNS)
32 Intranasal Steroids Prevent Antigen-Induced Hyperresponsiveness of the Nasal Ocular Response Completed NCT00473915 Phase 4 fluticasone furoate
33 A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Pharmacodynamic Effect of a 6-week Treatment With Triamcinolone Acetonide Aqueous Nasal Spray 110 μg and 220 μg Once Daily on Basal Hypothalamic-Pituitary-Adrenal (HPA) Axis Function in Children [>=2 to < 12 Years of Age] With Allergic Rhinitis (AR). Completed NCT01154153 Phase 4 Placebo nasal spray;Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ);Placebo nasal spray;Claritin® Syrup
34 Clinical Trial to Assess Onset of Action of Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray Delivered in a Single Spray (MP-AzeFlu) in the Treatment of Allergen-Induced Allergic Rhinitis Symptoms in Comparison to Placebo and Free Combination of Fluticasone Propionate Nasal Spray and Oral Loratadine Completed NCT03004131 Phase 4 Azelastine hydrochloride + fluticasone propionate nasal spray;Placebos;fluticasone propionate nasal spray + loratadine
35 Efficacy and Safety of Lectranal® in Treatment of Seasonal Allergic Rhinitis Symptoms Completed NCT00460538 Phase 4
36 Double-blind, Three Parallel Randomized Groups, Therapeutic Confirmatory Clinical Trial to Compare the Efficacy of Oral Levocetirizine 5 mg and Montelukast 10 mg to Placebo in Reducing Symptoms of Seasonal Allergic Rhinitis (SAR) in Ragweed Sensitive Subjects Exposed to Ragweed Pollen in an Environmental Exposure Unit (EEU) Completed NCT00295022 Phase 4 Placebo;Montelukast;Levocetirizine
37 A Pilot, Open, Monocenter, Randomized Two Parallel Groups, Clinical Efficacy Trial: Comparison Continuous Versus on Demand Regimen of Treatment With Levocetirizine 5 mg Oral Tablets, Once a Day, in Adults Suffering From Persistent Allergic Rhinitis (PER) Over 6 Months Completed NCT00160680 Phase 4 Levocetirizine
38 A Multicentre, Double-blind, Parallel, Randomized, Placebo-controlled Study : Evaluation of the Efficacy and Safety of Levocetirizine 5 mg and Desloratadine 5 mg Administered Orally as Capsules Once Daily, in the Morning, Over 2 Weeks in Patients Suffering From Allergic Rhinitis (AR) Completed NCT00160589 Phase 4 Levocetirizine
39 A Monocenter, Double-blind, Randomized Trial, With Two Parallel Groups Comparing the Clinical Efficacy of Levocetirizine 5 mg Capsules and Desloratadine 5 mg Capsules Taken Once a Day Over 3 Weeks of Treatment in Adult Subjects Suffering From Seasonal Allergic Rhinitis (SAR) Due to Grass Pollen Completed NCT00160537 Phase 4 Levocetirizine
40 A Comparison of Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis Completed NCT00502775 Phase 4 fluticasone furoate, fexofenadine
41 Efficacy and Safety of Nasonex vs. Placebo in Subjects With SAR and Concomitant Asthma Completed NCT00070707 Phase 4 Mometasone;Placebo;Albuterol/Salbutamol
42 Efficacy of Mite Allergen Vaccine Among Thai Patients With Allergic Rhinitis Completed NCT01115595 Phase 4
43 A Phase IV, Open-label, Safety and Tolerability Trial of MK-3641 and MK-7243 Coadministered in Subjects At Least 18 Years of Age With Ragweed and Grass Pollen Induced Allergic Rhinitis With or Without Conjunctivitis Completed NCT02256553 Phase 4 Rescue Medication
44 Regulatory Lymphocytes (Treg) in the Modulation of Allergic Inflammation in Patients Treated With Specific Immunotherapy. Completed NCT01475188 Phase 4 Allergovit
45 The Addition of Vitamin D to Fluticasone Propionate in the Management of Seasonal Allergic Rhinitis Completed NCT01103934 Phase 4 Vitamin D3;Placebo;Fluticasone Propionate
46 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Effects of a One-Year Course of Fluticasone Furoate Nasal Spray 110mcg QD on Growth in Pre-Pubescent, Pediatric Subjects With Perennial Allergic Rhinitis Completed NCT00570492 Phase 4 Fluticasone furoate nasal spray;Placebo nasal spray
47 A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine 5 mg Once Daily Given for 2 Weeks in Subjects 18 yr of Age and Older With Seasonal Allergic Rhinitis Completed NCT00621959 Phase 4 levocetirizine dihydrochloride;placebo
48 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of Fluticasone Furoate Nasal Spray 110mcg in Adult and Adolescent Subjects 12 Years of Age and Older With Perennial Allergic Rhinitis (PAR) Completed NCT00609674 Phase 4 Fluticasone furoate nasal spray;Placebo
49 A Four-Way Double-Blind, Randomized, Placebo Controlled Study to Determine the Efficacy and Speed of Azelastine Nasal Spray and Antihistaminic Agents in Adult Subjects With Allergen Induced Seasonal Allergic Rhinitis Completed NCT00561717 Phase 4 Azelastine and placebo;Loratadine and Placebo;Cetirizine and Placebo;Placebo and Placebo (spray and Tablet)
50 Montelukast as a Controller of Atopic Syndrome Completed NCT00559546 Phase 4 montelukast

Search NIH Clinical Center for Rhinitis

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Ephedra vulgaris preparation
Ephedrine
Ephedrine hydrochloride
Ephedrine sulfate
EPHEDRINE TANNATE
Hyoscyamine
Hyoscyamine hydrobromide
Hyoscyamine Sulfate
Naphazoline
Naphazoline Hydrochloride
Oxymetazoline
Oxymetazoline hydrochloride
Phenylpropanolamine

Cochrane evidence based reviews: rhinitis

Genetic Tests for Rhinitis

Genetic tests related to Rhinitis:

# Genetic test Affiliating Genes
1 Rhinitis 29

Anatomical Context for Rhinitis

MalaCards organs/tissues related to Rhinitis:

40
Skin, T Cells, Eye, Pituitary, Neutrophil, B Cells, Endothelial

Publications for Rhinitis

Articles related to Rhinitis:

(show top 50) (show all 28118)
# Title Authors PMID Year
1
The role of mast cell-derived secreted phospholipases A2 in respiratory allergy. 61 54
20219624 2010
2
[Evaluating total serum IgE levels and peripheral eosinophil count in asthma and rhinitis]. 54 61
20502102 2010
3
Reduced helminth burden increases allergen skin sensitization but not clinical allergy: a randomized, double-blind, placebo-controlled trial in Vietnam. 54 61
19758373 2010
4
Nasal inflammatory mediators and specific IgE production after nasal challenge with grass pollen in local allergic rhinitis. 61 54
19796796 2009
5
Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study. 54 61
18948425 2009
6
Association of single nucleotide polymorphisms in the eosinophil peroxidase gene with allergic rhinitis in the Czech population. 54 61
19439985 2009
7
Advances in upper airway diseases and allergen immunotherapy in 2007. 54 61
18694591 2008
8
Rhinitis and onset of asthma: a longitudinal population-based study. 61 54
18805333 2008
9
Change in prevalence of atopic dermatitis between 1986 and 2001 among children. 54 61
18702887 2008
10
Paediatric allergy diagnosis in primary care is improved by in vitro allergen-specific IgE testing. 54 61
18312533 2008
11
Recent progress in allergen immunotherapy. 61 54
18319521 2008
12
Patterns of GATA3 and IL13 gene polymorphisms associated with childhood rhinitis and atopy in a birth cohort. 61 54
18037162 2008
13
Quantification of atopy and the probability of rhinitis in preschool children: a population-based birth cohort study. 54 61
17822449 2007
14
A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma. 54 61
19075985 2007
15
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. 61 54
17886253 2007
16
[Clinical observation on treatment of children's mild continuous asthma by Fangchuan Mixture combined with flixotide]. 61 54
18173144 2007
17
Anti-IgE in allergic asthma and rhinitis: an update. 54 61
17961096 2007
18
Systemic and local eosinophil inflammation during the birch pollen season in allergic patients with predominant rhinitis or asthma. 61 54
17967188 2007
19
Allergic asthma and rhinitis caused by household rabbit exposure: identification of serum-specific IgE and its allergens. 54 61
17982229 2007
20
Polymorphisms of histamine-metabolizing enzymes and clinical manifestations of asthma and allergic rhinitis. 61 54
17651147 2007
21
Up-regulation of protease-activated receptor 2 in allergic rhinitis. 61 54
17727088 2007
22
Cysteinyl-leukotriene levels in sputum differentiate asthma from rhinitis patients with or without bronchial hyperresponsiveness. 54 61
17581201 2007
23
Mediators and cytokines in allergic and viral-triggered rhinitis. 54 61
17883911 2007
24
Asthma and rhinitis symptoms in individuals from different socioeconomic levels in a Brazilian city. 61 54
17619568 2007
25
Local IgE production and positive nasal provocation test in patients with persistent nonallergic rhinitis. 61 54
17337294 2007
26
What's new in paediatric sleep? 61 54
17419982 2007
27
Inverse relation between nasal fluid Clara Cell Protein 16 levels and symptoms and signs of rhinitis in allergen-challenged patients with intermittent allergic rhinitis. 54 61
17298427 2007
28
Applicability of extracellular electrical impedance tomography in monitoring respiratory tract inflammation. 54 61
17323861 2007
29
Subjects with non-allergic non-infectious perennial rhinitis do not show nasal hyper-responsiveness to bradykinin. 54 61
17043856 2007
30
Uteroglobin-related protein 1 and clara cell protein in induced sputum of patients with asthma and rhinitis. 54 61
17218572 2007
31
Eosinophil cationic protein, specific IgE and IgG4 in human toxocariasis. 54 61
17125552 2006
32
The role of allergic rhinitis in nasal responses to sudden temperature changes. 61 54
17088139 2006
33
Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab. 54 61
16949266 2006
34
[Is the seric eosinophil cationic protein level a valuable tool of diagnosis in clinical practice?]. 54 61
16647168 2006
35
Association between angiotensin-converting enzyme gene polymorphism and childhood allergic rhinitis in Taiwan. 61 54
16926975 2006
36
Atopy patch testing in children with asthma and rhinitis symptoms allergic to house dust mite. 54 61
16846452 2006
37
Intercellular adhesion molecule 1 and tumor necrosis factor alpha in asthma and persistent allergic rhinitis: relationship with disease severity. 54 61
16892784 2006
38
Determination of structure and transcriptional regulation of CYSLTR1 and an association study with asthma and rhinitis. 54 61
16771777 2006
39
Low prevalence of the intrinsic form of atopic dermatitis among adult patients. 54 61
16629795 2006
40
Allergen-induced interleukin-9 production in vitro: correlation with atopy in human adults and comparison with interleukin-5 and interleukin-13. 61 54
16433854 2006
41
Sensitization to blackgram in patients with bronchial asthma and rhinitis: clinical evaluation and characterization of allergens. 61 54
16364164 2006
42
Lack of association between the IL13 variant Arg110Gln and susceptibility to cedar pollinosis in a Japanese population. 61 54
16272823 2006
43
[Serum eosinophil cationic protein (ECP) in patients with perennial rhinitis and atopic dermatitis, allergic to house dust mites]. 61 54
16521419 2005
44
Efficacy of intramuscular BCG polysaccharide nucleotide on mild to moderate bronchial asthma accompanied with allergic rhinitis: a randomized, double blind, placebo-controlled study. 54 61
16232343 2005
45
Major lymphocyte populations and T-cell expression of ICAM-1 and L-selectin adhesion molecules in Kuwaitis with asthma and rhinitis. 61 54
17290844 2005
46
Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus. 61 54
15990782 2005
47
Low levels of CC16 in nasal fluid of children with birch pollen-induced rhinitis. 54 61
15813809 2005
48
Immunological characterization of a recombinant tropomyosin from a new indoor source, Lepisma saccharina. 61 54
15836758 2005
49
Aspirin sensitivity: implications for patients with coronary artery disease. 61 54
15613671 2004
50
A double-blind, randomized, placebo-controlled trial of acupuncture for the treatment of childhood persistent allergic rhinitis. 54 61
15520102 2004

Variations for Rhinitis

Expression for Rhinitis

Search GEO for disease gene expression data for Rhinitis.

Pathways for Rhinitis

Pathways related to Rhinitis according to GeneCards Suite gene sharing:

(show all 37)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.94 VCAM1 RNASE3 POMC IL5 IL4R IL4
2
Show member pathways
13.64 NR3C1 NGF IL5 IL4R IL4 IL13
3
Show member pathways
13.5 NGF IL5 IL4R IL4 IL13 ICAM1
4
Show member pathways
13.37 NGF IL5 IL4R IL4 IL13 CXCL8
5
Show member pathways
13.25 VCAM1 POMC IL5 IL4R IL4 IL13
6
Show member pathways
13.24 NGF IL5 IL4R IL4 IL13 CXCL8
7
Show member pathways
12.8 RNASE3 IL5 IL4 IL13 ICAM1 EPX
8 12.79 KNG1 IL5 IL4R IL4 IL13 CXCL8
9
Show member pathways
12.36 IL5 IL4R IL4 IL13
10
Show member pathways
12.34 IL4R IL4 IGHE HRH1 CCL11
11
Show member pathways
12.29 ICAM1 CXCL8 CCL5 CCL11
12
Show member pathways
12.28 IL5 IL4 IL13 CXCL8 CCL11
13
Show member pathways
12.24 NGF IL5 IL4 IL13 CXCL8
14 12.15 NR3C1 NGF IL13 CXCL8
15 11.85 VCAM1 ICAM1 CXCL8
16 11.84 IL5 IL4R IL4
17 11.81 ICAM1 CXCL8 CCL5
18 11.74 IL5 IL4 IL13
19
Show member pathways
11.71 IL5 IL4 CXCL8
20 11.63 VCAM1 IL5 IL4 ICAM1
21 11.63 IL5 IL4R IL4 IGHE CCL11
22
Show member pathways
11.6 VCAM1 NR3C1 ICAM1 CXCL8
23 11.52 VCAM1 ICAM1 CXCL8
24 11.46 IL4 IL13 ICAM1 CXCL8 CCL5
25 11.45 VCAM1 ICAM1 CXCL8
26 11.43 IL5 IL4 IL13 CXCL8 CCL5 CCL11
27 11.41 POMC NR3C1 IL5 IL4 IL13 ICAM1
28 11.38 IL5 IL4R IL4 IL13 CCL11
29 11.36 VCAM1 KNG1 ICAM1
30 11.33 VCAM1 POMC IL4R IL4 IL13 IGHE
31 11.3 IL5 IL4R IL4
32 11.28 IL5 IL4 IL13
33 11.22 IL5 IL4 IL13
34 11.16 IL5 IL4 IL13
35 10.93 VCAM1 IL4R IL4
36 10.92 NGF IL5 IL4 IL13 CXCL8 CCL5
37 10.64 IL5 IL4R IL4 IL13

GO Terms for Rhinitis

Cellular components related to Rhinitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 RNASE3 POMC NGF KNG1 IL5 IL4R
2 extracellular space GO:0005615 9.47 VCAM1 RNASE3 POMC NGF KNG1 IL5

Biological processes related to Rhinitis according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.18 POMC NR3C1 IL5 IL4R IL4 HRH1
2 G protein-coupled receptor signaling pathway GO:0007186 10.12 POMC KNG1 HRH1 CYSLTR1 CXCL8 CCL5
3 positive regulation of cold-induced thermogenesis GO:0120162 9.81 IL4R IL4 IL13
4 cellular response to interferon-gamma GO:0071346 9.8 ICAM1 CCL5 CCL11
5 neutrophil chemotaxis GO:0030593 9.78 CXCL8 CCL5 CCL11
6 chemokine-mediated signaling pathway GO:0070098 9.77 CXCL8 CCL5 CCL11
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.77 IL4 IL13 CCL5
8 chemotaxis GO:0006935 9.77 RNASE3 CYSLTR1 CXCL8 CCL5 CCL11
9 positive regulation of T cell proliferation GO:0042102 9.74 VCAM1 IL4 CCL5
10 cellular response to interleukin-1 GO:0071347 9.73 ICAM1 CXCL8 CCL5 CCL11
11 positive regulation of B cell proliferation GO:0030890 9.72 IL5 IL4 IL13
12 cellular response to tumor necrosis factor GO:0071356 9.72 VCAM1 ICAM1 CXCL8 CCL5 CCL11
13 negative regulation of endothelial cell apoptotic process GO:2000352 9.71 IL4 IL13 ICAM1
14 inflammatory response GO:0006954 9.7 KNG1 IL5 IL13 HRH1 CXCL8 CCL5
15 leukocyte cell-cell adhesion GO:0007159 9.67 VCAM1 ICAM1 CCL5
16 positive regulation of immunoglobulin production GO:0002639 9.63 IL5 IL4R IL13
17 negative regulation of G protein-coupled receptor signaling pathway GO:0045744 9.62 CXCL8 CCL5
18 neutrophil activation GO:0042119 9.62 CXCL8 CCL5
19 macrophage activation GO:0042116 9.61 IL4 IL13
20 chronic inflammatory response GO:0002544 9.58 VCAM1 CCL11
21 eosinophil chemotaxis GO:0048245 9.58 HRH1 CCL5 CCL11
22 membrane to membrane docking GO:0022614 9.56 VCAM1 ICAM1
23 immune response GO:0006955 9.56 IL5 IL4R IL4 IL13 IGHE CXCL8
24 negative regulation of complement-dependent cytotoxicity GO:1903660 9.52 IL4 IL13
25 positive regulation of cellular biosynthetic process GO:0031328 9.51 CXCL8 CCL5
26 positive regulation of mast cell degranulation GO:0043306 9.43 IL4R IL4 IL13
27 cytokine-mediated signaling pathway GO:0019221 9.36 VCAM1 POMC IL5 IL4R IL4 IL13

Molecular functions related to Rhinitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine activity GO:0008009 9.13 CXCL8 CCL5 CCL11
2 cytokine activity GO:0005125 9.1 IL5 IL4 IL13 CXCL8 CCL5 CCL11

Sources for Rhinitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....